非透明细胞肾细胞癌患者的肿瘤学结局：未分类和易位性肾细胞癌亚型
Oncological Outcomes of Patients with Non-Clear Cell Renal Cell Cancers: Subtypes of Unclassified and Translocation Renal Cell Cancers.
作者信息
Gokalp Fatih, Celik Serdar, Sozen Tevfik Sinan, Ozen Abdurrahim Haluk, Aslan Guven, Izol Volkan, Baltaci Sumer, Muezzinoglu Talha, Akdogan Bulent, Suer Evren, Tinay Ilker
机构信息
Department of Urology, Hatay Mustafa Kemal University, School of Medicine, Hatay.
Department of Urology, Bozyaka Training and Research Hospital, Izmir.
出版信息
Urol J. 2022 Dec 25;20(1):29-33. doi: 10.22037/uj.v19i.7091.
PURPOSE
We aimed to compare oncological outcomes in the two rare subtypes, unclassified renal cell cancer (unRCC) and translocation RCC (tRCC), vs clear cell RCC (ccRCC).
MATERIALS AND METHODS
Between 2004 and 2019, from Turkish Urooncology Society Database, we identified 2324 patients for histological subtypes including 80 unRCC (3.4%), 19 tRCC (0.8%) and 2225 ccRCC (95.8%).
RESULTS
The overall (15.8%) and cancer-specific mortalities (11.1%) were found to be higher in tRCC group and the recurrence free mortality (13.8%) was found to be higher in unRCC group. Larger pathological tumor size (p = 0.012) and advanced pathological T stage (p = 0.042) were independent predictive factors on overall mortality in patients with unRCC tumors.
CONCLUSION
The oncological outcomes of the unRCC and tRCC are worse than ccRCC and pathological tumor size and pathological stage are predictive factors for mortality in the unRCC.
目的
我们旨在比较两种罕见亚型，即未分类肾细胞癌（unRCC）和易位性肾细胞癌（tRCC）与透明细胞肾细胞癌（ccRCC）的肿瘤学结局。
材料与方法
2004年至2019年间，我们从土耳其泌尿肿瘤学会数据库中识别出2324例具有组织学亚型的患者，其中包括80例未分类肾细胞癌（3.4%）、19例易位性肾细胞癌（0.8%）和2225例透明细胞肾细胞癌（95.8%）。
结果
发现tRCC组的总死亡率（15.8%）和癌症特异性死亡率（11.1%）较高，而unRCC组的无复发生存率（13.8%）较高。较大的病理肿瘤大小（p = 0.012）和晚期病理T分期（p = 0.042）是unRCC肿瘤患者总死亡率的独立预测因素。
结论
unRCC和tRCC的肿瘤学结局比ccRCC差，病理肿瘤大小和病理分期是unRCC死亡率的预测因素。
Zotero 插件